{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:02:02Z","timestamp":1785438122899,"version":"3.56.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.phrs.2018.04.018","type":"journal-article","created":{"date-parts":[[2018,4,22]],"date-time":"2018-04-22T18:04:59Z","timestamp":1524420299000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Sodium glucose cotransporters inhibitors in type 1 diabetes"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7133-4740","authenticated-orcid":false,"given":"Sergio","family":"Dellepiane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moufida","family":"Ben Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Assi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Usuelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Letizia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"D\u2019Addio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Vincenzo","family":"Zuccotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fiorina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2018.04.018_bib0005","doi-asserted-by":"crossref","unstructured":"L. Huo, et al., Life expectancy of type 1 diabetic patients during 1997\u20132010: a national Australian registry-based cohort study. PubMed \u2013 NCBI, 2017.","DOI":"10.1007\/s00125-015-3857-4"},{"key":"10.1016\/j.phrs.2018.04.018_bib0010","doi-asserted-by":"crossref","unstructured":"D. Petrie, et al., Recent trends in life expectancy for people with type 1 diabetes in Sweden. PubMed \u2013 NCBI, 2017.","DOI":"10.1007\/s00125-016-3914-7"},{"key":"10.1016\/j.phrs.2018.04.018_bib0015","unstructured":"S.K. Garg, et al., Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. PubMed \u2013 NCBI, 2017."},{"key":"10.1016\/j.phrs.2018.04.018_bib0020","doi-asserted-by":"crossref","unstructured":"J. Janssen, et al., Serum insulin bioassay reflects insulin sensitivity and requirements in type 1 diabetes. PubMed \u2013 NCBI, 2017.","DOI":"10.1210\/jc.2017-00892"},{"key":"10.1016\/j.phrs.2018.04.018_bib0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.phrs.2014.06.016","article-title":"Novel immunological strategies for islet transplantation","volume":"98","author":"Tezza","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.04.018_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.03.019","article-title":"Novel therapies for T1D on the horizon","volume":"98","author":"Ben Nasr","year":"2015","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.phrs.2018.04.018_bib0035","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2337\/db13-1639","article-title":"Interleukin-10+ regulatory B cells arise within antigen-experienced CD40+ B cells to maintain tolerance to islet autoantigens","volume":"64","author":"Kleffel","year":"2015","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.phrs.2018.04.018_bib0040","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11892-011-0211-1","article-title":"Impact of islet transplantation on diabetes complications and quality of life","volume":"11","author":"Bassi","year":"2011","journal-title":"Curr. Diab. Rep."},{"issue":"416","key":"10.1016\/j.phrs.2018.04.018_bib0045","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7543","article-title":"PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes","volume":"9","author":"Ben Nasr","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2018.04.018_bib0050","series-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","author":"Zinman","year":"2015"},{"key":"10.1016\/j.phrs.2018.04.018_bib0055","unstructured":"A.T. Sands, et al., Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. PubMed \u2013 NCBI, 2017."},{"key":"10.1016\/j.phrs.2018.04.018_bib0060","unstructured":"A.T. Scheepers, et al., The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. PubMed \u2013 NCBI, 2017."},{"key":"10.1016\/j.phrs.2018.04.018_bib0065","unstructured":"J. Chen, et al., Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. PubMed \u2013 NCBI, 2017."},{"key":"10.1016\/j.phrs.2018.04.018_bib0070","doi-asserted-by":"crossref","unstructured":"X.X. Wang, et al., SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and \u2026 PubMed \u2013 NCBI, 2017.","DOI":"10.1074\/jbc.M117.779520"},{"key":"10.1016\/j.phrs.2018.04.018_bib0075","series-title":"SGLT2 Expression is increased in Human Diabetic Nephropathy: SGLT2 Inhibition Decreases Renal Lipid Accumulation, Inflammation and the Development of Nephropathy in Diabetic Mice","author":"Wang","year":"2017"},{"issue":"1","key":"10.1016\/j.phrs.2018.04.018_bib0080","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00125-015-3766-6","article-title":"CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease","volume":"59","author":"Bassi","year":"2016","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.phrs.2018.04.018_bib0085","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1681\/ASN.2013050518","article-title":"Role of podocyte B7-1 in diabetic nephropathy","volume":"25","author":"Fiorina","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.phrs.2018.04.018_bib0090","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.semnephrol.2012.07.006","article-title":"Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy?","volume":"32","author":"Doria","year":"2012","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.phrs.2018.04.018_bib0095","unstructured":"M.A. Niewczas, et al., Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. PubMed \u2013 NCBI, 2017."},{"issue":"25","key":"10.1016\/j.phrs.2018.04.018_bib0100","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1304572","article-title":"Abatacept in B7-1-positive proteinuric kidney disease","volume":"369","author":"Yu","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.04.018_bib0105","unstructured":"J.R. Ehrenkranz, et al., Phlorizin: a review. PubMed \u2013 NCBI, 2017."},{"key":"10.1016\/j.phrs.2018.04.018_bib0110","unstructured":"J.D. Loike, et al., Sodium-glucose cotransporters display sodium- and Phlorizin-dependent water permeability. PubMed \u2013 NCBI, 2017."},{"key":"10.1016\/j.phrs.2018.04.018_bib0115","unstructured":"C. Gosch, et al., Phloridzin: biosynthesis, distribution and physiological relevance in plants. PubMed \u2013 NCBI, 2017."},{"issue":"11","key":"10.1016\/j.phrs.2018.04.018_bib0120","doi-asserted-by":"crossref","first-page":"G946","DOI":"10.1152\/ajpgi.00286.2014","article-title":"Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release","volume":"308","author":"Dobbins","year":"2015","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.phrs.2018.04.018_bib0125","doi-asserted-by":"crossref","unstructured":"L. Seman, et al., Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects. PubMed \u2013 NCBI, 2017.","DOI":"10.1002\/cpdd.16"},{"issue":"5","key":"10.1016\/j.phrs.2018.04.018_bib0130","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","article-title":"Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2018.04.018_bib0135","unstructured":"S. Macha, et al., Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. PubMed \u2013 NCBI, 2017."},{"key":"10.1016\/j.phrs.2018.04.018_bib0140","unstructured":"M.A. Nauck, et al., Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is\u2026 PubMed \u2013 NCBI, 2017."},{"key":"10.1016\/j.phrs.2018.04.018_bib0145","unstructured":"J. Rosenstock, et al., Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyper\u2026 PubMed \u2013 NCBI, 2017."},{"key":"10.1016\/j.phrs.2018.04.018_bib0150","unstructured":"C.J. Bailey, et al., Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. PubMed \u2013 NCBI, 2017."},{"key":"10.1016\/j.phrs.2018.04.018_bib0155","unstructured":"R.R. Henry, et al., Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. PubMed \u2013 NCBI, 2017."},{"issue":"6","key":"10.1016\/j.phrs.2018.04.018_bib0160","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22\u202f528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.phrs.2018.04.018_bib0165","unstructured":"B. Bode, et al., Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55\u201380 years with type 2 diabetes. PubMed \u2013 NCBI. 2017."},{"key":"10.1016\/j.phrs.2018.04.018_bib0170","unstructured":"Y. Lytvyn, et al., Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. PubMed \u2013 NCBI, 2017."},{"issue":"4","key":"10.1016\/j.phrs.2018.04.018_bib0175","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/dom.12439","article-title":"Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus","volume":"17","author":"Davies","year":"2015","journal-title":"Diab. Obes. Metab."},{"key":"10.1016\/j.phrs.2018.04.018_bib0180","unstructured":"J. Bolinder, et al., Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with in\u2026 PubMed \u2013 NCBI, 2017."},{"key":"10.1016\/j.phrs.2018.04.018_bib0185","series-title":"Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension","author":"Tikkanen","year":"2015"},{"key":"10.1016\/j.phrs.2018.04.018_bib0190","unstructured":"D.Z. Cherney, et al., The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. PubMed \u2013 NCBI, 2017."},{"key":"10.1016\/j.phrs.2018.04.018_bib0195","series-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","author":"Neal","year":"2017"},{"key":"10.1016\/j.phrs.2018.04.018_bib0200","unstructured":"M.A. Weber, et al., Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. PubMed \u2013 NCBI, 2017."},{"key":"10.1016\/j.phrs.2018.04.018_bib0205","series-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","author":"Ferrannini","year":"2014"},{"issue":"9","key":"10.1016\/j.phrs.2018.04.018_bib0210","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1507\/endocrj.EJ17-0065","article-title":"Effect of canagliflozin on circulating active GLP-1 levels in patients with type 2 diabetes: a randomized trial","volume":"64","author":"Takebayashi","year":"2017","journal-title":"Endocr. J."},{"key":"10.1016\/j.phrs.2018.04.018_bib0215","doi-asserted-by":"crossref","unstructured":"S. Verma, et al., The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure. PubMed \u2013 NCBI, 2017.","DOI":"10.1001\/jamacardio.2017.1891"},{"key":"10.1016\/j.phrs.2018.04.018_bib0220","doi-asserted-by":"crossref","unstructured":"M. Packer, et al., Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. PubMed \u2013 NCBI, 2017.","DOI":"10.1001\/jamacardio.2017.2275"},{"key":"10.1016\/j.phrs.2018.04.018_bib0225","series-title":"Diabetic Kidney Disease\u2014A Clinical Update from Kidney Disease: Improving Global Outcomes (KDIGO)","author":"Molitch","year":"2015"},{"issue":"5","key":"10.1016\/j.phrs.2018.04.018_bib0230","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/ki.2014.246","article-title":"Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes","volume":"86","year":"2014","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.phrs.2018.04.018_bib0235","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/1479164114563304","article-title":"Development of sotagliflozin, a dual sodium-dependent glucose transporter 1\/2 inhibitor","volume":"12","author":"Lapuerta","year":"2015","journal-title":"Diab. Vasc. Dis. Res."},{"issue":"2","key":"10.1016\/j.phrs.2018.04.018_bib0240","doi-asserted-by":"crossref","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","article-title":"Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia","volume":"306","author":"Rieg","year":"2014","journal-title":"Am. J. Physiol. Renal. Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2018.04.018_bib0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1084\/jem.16.1.1","article-title":"The effect of certain experimental procedures on the Islands of Langerhans","volume":"16","author":"Cecil","year":"1912","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.phrs.2018.04.018_bib0250","first-page":"344","article-title":"Phlorizin glycosuria in the diagnosis of pregnancy","volume":"20","author":"Hollingsworth","year":"1922","journal-title":"Cal. State J. Med."},{"issue":"6","key":"10.1016\/j.phrs.2018.04.018_bib0255","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1172\/JCI100559","article-title":"The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man","volume":"12","author":"Chasis","year":"1933","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2018.04.018_bib0260","unstructured":"L. Rossetti, et al., Correction of hyperglycemia with Phlorizin normalizes tissue sensitivity to insulin in diabetic rats. PubMed \u2013 NCBI, 2017."},{"key":"10.1016\/j.phrs.2018.04.018_bib0265","doi-asserted-by":"crossref","unstructured":"L. Rossetti, et al., Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. PubMed \u2013 NCBI, 1987.","DOI":"10.1172\/JCI113157"},{"key":"10.1016\/j.phrs.2018.04.018_bib0270","doi-asserted-by":"crossref","unstructured":"S.T. Cheng, et al., The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic \u03b2-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PubMed \u2013 NCBI, 2017.","DOI":"10.1371\/journal.pone.0147391"},{"key":"10.1016\/j.phrs.2018.04.018_bib0275","series-title":"Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes","author":"Powell","year":"2015"},{"issue":"5","key":"10.1016\/j.phrs.2018.04.018_bib0280","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.phrs.2018.04.018_bib0285","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc13-2338","article-title":"Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial","volume":"37","author":"Perkins","year":"2014","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.phrs.2018.04.018_bib0290","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/dom.12494","article-title":"Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)","volume":"17","author":"Pieber","year":"2015","journal-title":"Diab. Obes. Metab."},{"key":"10.1016\/j.phrs.2018.04.018_bib0295","unstructured":"H.E. Tamez, et al., Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus. PubMed \u2013 NCBI, 2017."},{"issue":"3","key":"10.1016\/j.phrs.2018.04.018_bib0300","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc13-2955","article-title":"Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2018.04.018_bib0305","unstructured":"R.R. Henry, et al., Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. PubMed \u2013 NCBI, 2017."},{"key":"10.1016\/j.phrs.2018.04.018_bib0310","doi-asserted-by":"crossref","unstructured":"H. Tang, et al., SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. PubMed \u2013 NCBI, 2017.","DOI":"10.1007\/s00125-017-4370-8"},{"key":"10.1016\/j.phrs.2018.04.018_bib0315","doi-asserted-by":"crossref","unstructured":"J. Chen, et al., The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. PubMed \u2013 NCBI, 2017.","DOI":"10.1038\/srep44128"},{"key":"10.1016\/j.phrs.2018.04.018_bib0320","doi-asserted-by":"crossref","unstructured":"J. Liu, et al., Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. PubMed \u2013 NCBI, 2017.","DOI":"10.1038\/s41598-017-02733-w"},{"key":"10.1016\/j.phrs.2018.04.018_bib0325","doi-asserted-by":"crossref","unstructured":"N.B. Watts, et al., Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. PubMed \u2013 NCBI, 2017.","DOI":"10.1210\/jc.2015-3167"},{"issue":"4","key":"10.1016\/j.phrs.2018.04.018_bib0330","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.phrs.2018.04.018_bib0335","doi-asserted-by":"crossref","unstructured":"J.P. Bilezikian, et al., Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. PubMed \u2013 NCBI, 2017.","DOI":"10.1210\/jc.2015-1860"},{"key":"10.1016\/j.phrs.2018.04.018_bib0340","doi-asserted-by":"crossref","unstructured":"H.L. Hang, et al., Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a netw\u2026 PubMed \u2013 NCBI, 2017.","DOI":"10.1111\/dom.12742"},{"key":"10.1016\/j.phrs.2018.04.018_bib0345","doi-asserted-by":"crossref","unstructured":"A. Egger, et al., Effects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health. PubMed \u2013 NCBI, 2017.","DOI":"10.1007\/s11914-016-0337-9"},{"key":"10.1016\/j.phrs.2018.04.018_bib0350","doi-asserted-by":"crossref","DOI":"10.1007\/s00592-018-1101-7","article-title":"Insulin resistance and bone: a biological partnership","author":"Conte","year":"2018","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.phrs.2018.04.018_bib0355","unstructured":"Z. Yuan, et al., Risk of Lower Extremity Amputations in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors in the United States: A Retrospective C\u2026 PubMed \u2013 NCBI, 2017."},{"key":"10.1016\/j.phrs.2018.04.018_bib0360","doi-asserted-by":"crossref","unstructured":"K. Johnsson, et al., Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials. PubMed \u2013 NCBI. 2017.","DOI":"10.1080\/00325481.2016.1153941"},{"key":"10.1016\/j.phrs.2018.04.018_bib0365","doi-asserted-by":"crossref","unstructured":"G.N. Nadkarni, et al., Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis. PubMed \u2013 NCBI, 2017.","DOI":"10.2337\/dc17-1011"},{"key":"10.1016\/j.phrs.2018.04.018_bib0370","series-title":"Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors","author":"Rosenstock","year":"2015"},{"key":"10.1016\/j.phrs.2018.04.018_bib0375","unstructured":"C. Bonner, et al., Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. PubMed \u2013 NCBI, 2017."},{"key":"10.1016\/j.phrs.2018.04.018_bib0380","unstructured":"C.H. Lhat, A Review on the Relationship between SGLT2 Inhibitors and Cancer. PubMed \u2013 NCBI, 2017."},{"issue":"6","key":"10.1016\/j.phrs.2018.04.018_bib0385","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00592-016-0856-y","article-title":"Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus","volume":"53","author":"Solini","year":"2016","journal-title":"Acta Diabetol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818302305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818302305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:53:23Z","timestamp":1760910803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661818302305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":77,"alternative-id":["S1043661818302305"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2018.04.018","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium glucose cotransporters inhibitors in type 1 diabetes","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2018.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}